

HR 2846

Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 26, 2021

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 27, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/2846>

Sponsor

Name: Rep. McKinley, David B. [R-WV-1]

Party: Republican • **State:** WV • **Chamber:** House

Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bass, Karen [D-CA-37]	D · CA		Apr 26, 2021
Rep. Carter, Earl L. "Buddy" [R-GA-1]	R · GA		Apr 26, 2021
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Apr 26, 2021
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Apr 26, 2021
Rep. Tonko, Paul [D-NY-20]	D · NY		Apr 26, 2021
Rep. Soto, Darren [D-FL-9]	D · FL		Apr 30, 2021
Rep. Kelly, Robin L. [D-IL-2]	D · IL		May 25, 2021
Rep. Welch, Peter [D-VT-At Large]	D · VT		Jun 8, 2021
Rep. Craig, Angie [D-MN-2]	D · MN		Jun 22, 2021
Rep. Grothman, Glenn [R-WI-6]	R · WI		Jul 1, 2021

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 27, 2021
Ways and Means Committee	House	Referred to	Apr 26, 2021
Ways and Means Committee	House	Referred to	Apr 26, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021

This bill establishes additional requirements for prescription drug plan (PDP) sponsors that use formularies under the Medicare prescription drug benefit.

Specifically, the bill requires PDP formularies to include covered generic drugs and biosimilars for which the wholesale acquisition cost is less than that of the reference (i.e., brand-name) product. PDP sponsors must also establish specific cost-sharing tiers that apply lower cost-sharing requirements for such covered generic drugs and biosimilars as compared to those for brand-name products.

The bill also prohibits PDP sponsors from instituting certain requirements relating to access to such covered generic drugs and biosimilars that are more restrictive than those for brand-name products (e.g., prior authorization requirements).

Actions Timeline

- **Apr 27, 2021:** Referred to the Subcommittee on Health.
- **Apr 26, 2021:** Introduced in House
- **Apr 26, 2021:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Apr 26, 2021:** Referred to the Subcommittee on Health.
- **Apr 26, 2021:** Referred to the Subcommittee on Social Security.